Kornimate/medical-research-clean huggingface dataset:
efficacy and safety study of platelets treated for pathogen inactivation and stored for up to seven days

Conditions: Thrombocytopenia

Summary: objective: to determine if platelets treated for pathogen inactivation and stored for 6 to 7 days are safe and effective compared to platelets collected by the same method, stored for the same amount of time and not treated for pathogen inactivation.

although the european commission directive 2004/33/ec states that platelet preparations may be stored for 7 days in conjunction with detection or reduction of bacterial contamination, most blood centers store platelets for only 4 or 5 days. extending the storage time could greatly improve platelet availability for patients while decreasing wastage of this limited resource.

Eligibility criteria:
inclusion criteria: * at least 16 years old * written informed consent * thrombocytopenia, or expected to develop thrombocytopenia requiring platelet transfusion within 15 days of randomization * undergoing one haematopoietic stem cell transplantation and/or admitted for treatment of acute or chronic leukaemia, lymphoma, multiple myeloma or myelodysplasia exclusion criteria: * refractoriness to platelet transfusion * immune-mediated thrombocytopenia, thrombotic thrombocytopenic purpura, or hemolytic uremic syndrome * use of il-11 (neumega®) or other investigational platelet growth factor * disseminated intravascular coagulation (dic) * clinically or radiologically detectable splenomegaly * previous participation in the study

Keywords: thrombocytopenic patients
effect of lidocaine on hemodynamic response and postoperative sore throat

Conditions: Postoperative Sore Throat

Summary: postoperative sore throat (post) is a common outcome of general anesthesia in patients who undergo endotracheal intubation, and the estimated risk varies between 14.4% and 62%. it is one of the most undesirable postoperative anesthesia complications and has a negative impact on patient satisfaction and quality. mucosal damage, inflammation, and erosion caused by endotracheal intubation all contribute to the development of post. therefore, post is a condition that requires prevention and improvement. in the study, patients will be divided into two groups. the investigators will include 100 patients undergoing surgery under general anesthesia. the first group will receive 40 mg of lidocaine hcl solution 5 minutes before endotracheal intubation, while the second group will receive standard anesthesia management as the control group. throat pain assessment will be conducted in patients at 2, 6, 12, and 24 hours after surgery.

between november 2023 and december 2023, a total of 100 patients aged 18-65 with asa 1-3 classification who are electively scheduled for laparoscopic cholecystectomy will participate in the study. patients with asa 4 or higher, those aged 65 and older, those under 18, and individuals with a known allergy to local anesthesia will not be included in the study. patients who require intubation and are admitted to the intensive care unit or who experience mortality will be excluded from the study. all patients will undergo preoperative assessment one day before the surgery, and written informed consent will be obtained for participation in the study. patients will be randomly assigned to groups using a computer-generated randomization table. patients in group 1 will receive 40 mg of lidocaine hcl solution 5 minutes before endotracheal intubation, while the second group will receive standard anesthesia management as the control group. demographic data, medical history, american society of anesthesiologists (asa) classification, and pre- and post-lidocaine administration cardiac output (co) and oxygen consumption (vo2), anesthesia time, surgical duration, as well as the occurrence of postoperative hypotension (systolic blood pressure decreased by more than 20% from baseline or sbp \ 45 mmhg), and agitation during the awakening period will be recorded. throat pain will be assessed and recorded at postoperative hours 2, 6, 12, and 24. throat pain will be evaluated using a throat pain scoring system ranging from 0 (no pain) to 3 (worst imaginable pain). after the surgery, all patients will be transferred to the post-anesthesia care unit (pacu).

Eligibility criteria:
inclusion criteria: * electively laparoscopic cholecystectomy. * asa i-iii, * between 18-65 years exclusion criteria: * asa iv and above • over 65 - under 18 years of age * lidocaine allergy
tennis elbow patients undergoing closed therapy can easily cause tendon tear

Conditions: Tennis Elbow; MRI; Hyperlipidemia

Summary: to explore whether there is a difference in the rate of tendon tear after hyperlipemia in tennis elbow patients and those with normal blood lipids after closed treatment, which provides clues for further exploration of its mechanism. 1. collect data from 108 cases of tennis elbow patients treated at the institute of sports medicine, peking university third hospital from january 2010 to december 2018 at the institute of sports medicine, peking university third hospital. statistics included the sex, age, bmi, number of closures, total cholesterol, triglycerides, low-density lipoprotein, high-density lipoprotein. 2. retrieve the mri imaging data of the above-mentioned patients, and use the extensor tendon at the humerus to see if there is a tear as an observation indicator. analyze the difference of tendon tear after closed treatment in patients with high blood fat and normal blood fat.


Eligibility criteria:
inclusion criteria: * all patients with tennis elbows in our hospital exclusion criteria: * none
study of trm-1(trail-r1 monoclonal antibody) in subjects with relapsed or refractory non-small cell lung cancer (nsclc)

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: the purpose of this study is to evaluate the efficacy and safety of trm-1 in subjects with relapsed or refractory non-small cell lung cancer.


Eligibility criteria:
primary inclusion criteria: * relapsed or refractory histologically or cytologically confirmed stage iiib, iv, or recurrent nsclc * previously treated and failed to respond to standard therapy or progressed after standard therapy * 18 years of age or older primary exclusion criteria: * received a non-fda approved investigational agent within the last 4 weeks. * previous cancer therapies (chemotherapy, hormonal therapy, monoclonal antibodies or radiation therapy) within the last 3 weeks, 8 weeks for fully human or humanized monoclonal antibodies * infection requiring antibiotics or hospitalization within the last 2 weeks * hiv, hepatitis-b, hepatitis-c * pregnant or breast-feeding women * major surgery within the last 4 weeks * history of other cancers within the past 5 years
the risk of acute myeloid leukaemia in patients with ewing's sarcoma

Conditions: Acute Myeloid Leukemia (AML); Ewing Sarcoma

Summary: ewing's sarcoma is an uncommon yet vital malignancy of bone. it demonstrates a predilection for the pediatric and young adult population. chemotherapy is considered an important treatment modality for ewing's sarcoma. however, the development of therapy-related leukemia, especially acute myeloid leukemia following treatment, is attributed to the use of substances such as alkylating agents and topoisomerase inhibitors which are genotoxic. there is a very few studies elaborating on the incidence rates of such complications. so, our aim is to quantify the risk of developing acute myeloid leukemia in ewing sarcoma patients and provide an updated evidence to the literature.


Eligibility criteria:
inclusion criteria: * patients diagnosed with ewing sarcoma * latency exclusion period of 6 months * sequence 0 or 1 exclusion criteria: * patients lacking age documentation or age reported only on death certificates or autopsies

Keywords: acute myeloid leukemia ewing sarcoma seer
a study of physical activity patterns and major health events in older people with implantable cardiac devices

Conditions: Physical Activity; Aging; Cardiac Disease

Summary: an observational study of physical activity patterns in 150 older adults with cardiac implantable electronic devices (cied)

study type: observational, investigator led study design: observational model: cohort (retrospective) population: 150 people over 60 years of age with a medtronic carelink® compatible cied in situ recruited from the manchester university nhs foundation trust, england, uk data collection: daily pa measures, demographic details, co-morbidity status, physical frailty assessment, functional status, quality of life (qol) and neha data consent: for participation in the study, physical frailty assessment, additional collection of retrospective cied data, and access to electronic patient records data sources: cied downloads, self-report questionnaire, physical measurements (height, weight, hand grip strength, gait speed), electronic hospital records, hes (hospital episode statistics) data results analysis: data will be analysed to investigate: daily pa variability; the association between pa and nehas, and the impact of frailty on pa patterns

Eligibility criteria:
inclusion criteria: 1. age 60+ years 2. functioning cied in situ for at least 6 months 3. medtronic manufactured device compatible with carelink® cardiac compass application (platform which measures and stores physiological parameters) 4. lives in the greater manchester area 5. able and willing to given written, informed consent to enter the study exclusion criteria: 1. faulty or incompatible device 2. immobile (unable to walk in upright position) 3. active participant in a clinical trial which does not allow concurrent recruitment into this study 4. people unable to consent in the english language (including the understanding of study literature which is published in english only)
edrn prostate mri biomarker study

Conditions: PSA; Prostate Cancer

Summary: the commercialization of mri fusion biopsies has resulted in a dramatic increase in the use of mri imaging for prostate cancer. how best to use mri in the initial prostate biopsy setting given the availability of validated prostate cancer early detection markers is uncertain.this study will allow investigators to determine if prostate mri is superior to validated panel of laboratory biomarkers (e.g. pca3, psa and tmprss2:erg) in the initial biopsy setting.

the primary aim of this study is to see if the addition of prostate mri to a panel consisting of psa, pca3, tmprss2:erg will significantly improve specificity for high-grade prostate cancer by 10%. the subsequent exploratory aims will 1) create an optimal panel of urine, blood and tissue biomarkers that will select those cases most likely to benefit from a mri targeted biopsy, 2) directly compare psa and urinary biomarkers with mri to determine which ones are value added in the setting of initial biopsy, 3) evaluate changes in these biomarkers and mri to determine if longitudinal changes predict subsequent high-grade prostate cancer, and 4) optimize mri imaging to improve test performance. importantly, this study will create a unique, prospective, cohort that will become the foundational reference set for of a range of future biomarker studies.

Eligibility criteria:
inclusion criteria: * men with suspected but undiagnosed prostate cancer * to be scheduled/scheduled for biopsy as routine clinical care exclusion criteria: * inability to obtain blood and urine per sop or conduct an attentive dre * unable to undergo/tolerate a prostate mri or failure to conduct the mri * prior diagnosis of prostate cancer * prior prostate mri unless being used as index mri (in this case index mri can be one year prior to consent date) * participating in clinical trial for prostate disease * prior prostate surgery such as turp, tuna, tumt, holep, rezum, urolift * prior pca3, tmprss2:erg or mips panel performed for clinical purpose

Keywords: prostate cancer psa early detection mri
efficacy and safety of tak-438 compared to ag-1749 (lansoprazole) in the treatment of duodenal ulcer

Conditions: Duodenal Ulcer

Summary: the purpose of this study is to determine the efficacy of tak-438, once daily (qd), compared to lansoprazole in patients with duodenal ulcer.


Eligibility criteria:
inclusion criteria: 1. participants must have endoscopically confirmed duodenal ulcers (mucosal defect with white coating) .at least one ulcer with white coating of 5 mm or larger in size should be observed at baseline (visit 1). 2. outpatient (including short inpatient for examination and others) exclusion criteria: 1. participants with a gastric ulcer which is suspected to be malignant on endoscopy at baseline (visit 1) 2. participants with an acute duodenal mucosal lesion (adml) on endoscopy at baseline (visit 1) 3. participants with a linear ulcer (including scarring) on endoscopy at baseline (visit 1) 4. participants with a postoperative ulcer (e.g., ulcer after emr/esd) on endoscopy at baseline (visit 1) 5. participants with a gastric ulcer on endoscopy at baseline (visit 1) 6. participants with an ulcer for which medical treatment is not indicated (e.g.,perforation, pyloric stenosis, duodenal stenosis, large hemorrhage) 7. participants who have received endoscopic hemostasis for gastric ulcer within 30 days prior to baseline (visit 1) 8. participants with a previous or current history of zollinger-ellison syndrome, or other gastric acid hypersecretion disorders 9. participants who have received or who are scheduled to undergo surgery which affects gastric acid secretion (e.g., resection of upper gastrointestinal tract, vagotomy)

Keywords: drug therapy
an exercise intervention study in insulin-resistant adolescents

Conditions: Insulin Resistance; Obesity

Summary: hypothesis: insulin-resistant african-american and hispanic adolescents will show significant improvement of insulin sensitivity (si) and positive changes associated with fibrinolytic markers and lipid profile after a two month supervised aerobic training.

the specific aims of the study are 1) to determine the effects of exercise on insulin sensitivity in insulin-resistant african-american and hispanic adolescents; 2) to determine the effects of exercise on fibrinolytic markers in insulin-resistant african-american and hispanic adolescents. the hypothesis is that insulin-resistant african-american and hispanic adolescents will show significant improvement of insulin sensitivity (si) and positive changes associated with fibrinolytic markers and lipid profile after a 1 month pre-training period and two-months of supervised, moderate intensity aerobic exercise. part i. insulin-resistant african american and hispanic adolescents from the dc metro area will be recruited through various recruitment efforts. potential participants will have 2 screening visits in which their medical history, physical activity level, body mass index, and fasting plasma glucose and insulin or ogtt results will determine eligibility. part 2. if inclusion criteria is met, the subjects will undergo a 2 week dietary stabilization period, treadmill exercise testing, ivgtt, blood draws for fibrinolytic and lipid markers, dexa scan, and anthropometric measurements. subjects will have a 1 month pre-training period and 2 months of supervised, moderate intensity aerobic exercise. all baseline testing will be repeated after the exercise period to see any significant differences.

Eligibility criteria:
inclusion criteria: * must be between 14 to 18 years old * being african american or hispanic * sedentary (exercising less than twice a week for less than 20 minutes) * non-smoker * at high risk of developing insulin resistance * bmi for age grater than or equal to the 95th percentile exclusion criteria: * history of chronic illnesses * thyroid dysfunction * taking medications know to affect metabolism * being pregnant or lactating
study to evaluate pf-04965842 in patients with moderate to severe psoriasis

Conditions: Plaque Psoriasis

Summary: study b7451005 is a phase 2 study which will assess the efficacy and safety of pf-04965842 in patients with moderate to severe psoriasis. the study will include three pf-04965842 groups (200 mg daily, 400 mg daily and 200 mg twice daily) and a placebo group. the treatment period will be 4 weeks in duration and will be followed up by a 4 week follow up period.


Eligibility criteria:
inclusion criteria: 1. have a diagnosis of plaque psoriasis for at least 6 months prior to first study dose. 2. have plaque type psoriasis covering at least 15% of total bsa at day 1 (at the time of the first study dose). 3. have a pasi score of 12 or greater at day 1 (at the time of the first study dose). 4. be a candidate for phototherapy or systemic treatment of psoriasis (either naïve or history of previous treatment). exclusion criteria: 1. currently have non plaque forms of psoriasis, eg, erythrodermic, guttate, or pustular psoriasis. 2. 3. have current drug induced psoriasis, eg, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, antimalarial drugs or lithium. 3. have received any of the following treatment regimens specified in the timeframes outlined below: within 9 months of first dose of study drug: • ustekinumab (stelara). within 12 weeks of first dose of study drug: • any experimental therapy for psoriasis or rheumatoid arthritis. within 4 8 weeks of first dose of study drug: * biologic therapies for psoriasis have discontinuation periods determined from approximately 5x half life of the respective biologic: * 4 weeks: etanercept (enbrel). * 8 weeks: infliximab (remicade), adalimumab (humira). within 4 weeks of first dose of study drug: * systemic treatments other than biologics that could affect psoriasis (eg, oral or injectable corticosteroids, retinoids, methotrexate, cyclosporine, fumaric acid derivatives, sulfasalazine, hydroxycarbamide (hydroxyurea), azathioprine). * phototherapy and psoralen plus ultraviolet a therapy (puva). * other - intramuscular gold, immunization with any live virus vaccination (eg, flumist), herbal medications. within 2 weeks of first dose of study drug: * topical treatments that could affect psoriasis (eg, corticosteroids, tars, keratolytics, anthralin, vitamin d analogs, and retinoids). * phototherapy with ultraviolet b (uvb) (narrowband or broadband).

Keywords: phase 2 randomized double-blind placebo plaque psoriasis safety efficacy jak janus kinase moderate severe
comparison of the ultrasound-guided paravertebral nerve block with liposomal bupivacaine versus ropivacaine for post-surgical pain after video-assisted thoracoscopic surgery

Conditions: Analgesia

Summary: prospective, randomized, and controlled trial to compare the postoperative pain management of paravertebral nerve block with liposomal bupivacaine to ropivacaine in patients undergoing elective thoracoscopic surgery.

the objective of this study is to validate the analgesic efficacy of liposomal bupivacaine (lb) compared with ropivacaine when injected for paravertebral nerve block (pvb) for video-assisted thoracoscopic surgery (vats). we hypothesize that lb will be superior to ropivacaine in terms of postoperative pain control following vats. the primary outcome of this study will be nrs pain scores for resting pain and nrs pain scores for cough pain 24 hours following surgery. secondary outcomes will include pain scores over the first 120 hours following surgery, opioid consumption, opioid-related adverse events, block-related adverse events, time of first getting out of bed, catheter indwelling time, postoperative hospitalization time, patient satisfaction, and chronic pain at 1, 3, and 6 months after surgery.

Eligibility criteria:
inclusion criteria: 1. age 18-64 years old 2. elective unilateral thoracoscopic surgery 3. hospital stay ≥3 days 4. able to cooperate in completing interviews and scale assessments 5. american society of anesthesiologists (asa) classification i-iii 6. signed informed consent form exclusion criteria: 1. history of thoracic surgery within the past 6 months 2. pre-existing history of chronic pain or acute pain in the surgical area 3. allergy to local anesthetics 4. contraindications to thoracic paravertebral nerve block 5. mental disorders, intellectual disabilities, epilepsy, or other neurological conditions 6. severe heart or lung diseases 7. history of opioid drug abuse or substance abuse 8. postoperative intubation 9. recent participation in other clinical studies

Keywords: paravertebral nerve block liposomal bupivacaine video-assisted thoracoscopic surgery
drainage of traumatic hemothorax and pneumothorax: small bore versus large bore chest drain

Conditions: Traumatic Hemothorax and Pneumothorax

Summary: the purpose of this trial is to study the role of small bore chest drains in draining traumatic hemothorax and pneumothorax.

the precise role of small bore chest drains in treating post traumatic pleural collections, especially hemothorax is not well established. this trial is conducted to study the efficacy and safety profile of small bore chest drains in trauma patients with hemothorax and pneumothorax.

Eligibility criteria:
inclusion criteria: * patients with traumatic hemothorax, pneumothorax and hemopneumothorax exclusion criteria: * patients with tension pneumothorax * patients requiring emergency thoracotomy * patients who had undergone chest drain insertion elsewhere * patients lost to follow up
contrast-enhanced ultrasound identification of sentinel nodes in esophageal cancer

Conditions: Esophagus

Summary: this pilot trial studies how well an ultrasound with a contrast agent (perflubutane microbubble \[sonazoid\]) works in identifying sentinel lymph nodes in participants with esophageal cancer. sentinel lymph nodes are lymph nodes to which the cancer is likely to spread from the primary tumor. diagnostic procedures, such as contrast-enhanced ultrasound, may work better in identifying sentinel lymph nodes and finding out how far the disease has spread.

primary objectives: i. to assess the accuracy of contrast-enhanced endoscopic lymphosonography guided fine-needle aspiration (fna) of sentinel lymph nodes compared with unenhanced endoscopic ultrasonography (eus) guided fna in the characterization of esophageal cancer-associated lymph nodes using pathology as the reference standard. secondary objectives: i. to assess the ability of contrast-enhanced endoscopic lymphosonography guided fna compared with unenhanced eus guided fna in the overall detection of biopsy proven cancer-involved sentinel lymph nodes. ii. to assess the impact of overall tumor staging by contrast-enhanced endoscopic lymphosonography compared with unenhanced eus.

Eligibility criteria:
inclusion criteria: * newly diagnosed with esophageal cancer. * be scheduled for staging endoscopic ultrasound with the intent for lymph node evaluation. * provide signed and dated informed consent form. * willing to comply with all study procedures and be available for the duration of the study. * be medically stable. * if a female and pre-menopausal, must have a negative pregnancy test. exclusion criteria: * females who are pregnant or nursing. * patients with other primary cancers requiring systemic treatment. * patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable. * patients with known hypersensitivity or allergy to any component of sonazoid. * patients with cardiac shunts or unstable cardiopulmonary conditions. * patients with congenital heart defects. * patients with severe emphysema, pulmonary vasculitis, pulmonary hypertension, respiratory distress syndrome, or a history of pulmonary embolism.